NuvOx Pharma announced that a manuscript describing results of the Company’s product dodecafluoropentane emulsion (DDFPe) in reducing damage from myocardial infarction (MI) has been published in the journal Cardiovascular Drugs and Therapy.
NuvOx Pharma, a Tucson based biotechnology company, announced that a manuscript describing results of the Company’s product dodecafluoropentane emulsion (DDFPe) in reducing damage from myocardial infarction (MI) has been published in the journal Cardiovascular Drugs and Therapy (Strom, Joshua, et al. “Dodecafluoropentane Emulsion Elicits Cardiac Protection Against Myocardial Infarction Through an ATP-Sensitive K+ Channel Dependent Mechanism.” Cardiovascular Drugs and Therapy (2014): 1-7).
In this study administration of a single dose of DDFPe decreased damage from myocardial infarction by 75%.
Dr. Larson, corresponding author on the paper, Professor of Surgery and Pharmacology at the University of Arizona said, “The results of DDFPe in this study are very promising. DDFPe could potentially be administered early in the treatment of heart attack to reduce damage to the heart and improve outcomes from MI. Since another formulation of DDFPe is already in clinical trials to treat brain cancer, DDFPe could potentially be tested in clinical trials relatively quickly to treat MI.” Dr. Larson further added, “NuvOx Pharma has licensed a patent application for this technology to treat MI from the University of Arizona.”